Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aligos Therapeutics SEC filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing therapies for liver and viral diseases. Its Form 8-K reports furnish results of operations, business progress updates, clinical and regulatory events for pevifoscorvir sodium, and material agreements such as the exclusive license for development and commercialization in Greater China.
Proxy materials cover annual meeting procedures, stockholder voting matters, board governance, and compensation-related disclosures. Other current reports document executive officer appointments, compensatory arrangements, exhibit filings, and the company’s common stock listed on the Nasdaq Capital Market under ALGS.
Aligos Therapeutics, Inc. reported a compensation-related stock option grant to officer Lesley Ann Calhoun. She was awarded options to acquire 37,485 shares of common stock at an exercise price of $7.03 per share, expiring on March 9, 2036.
According to the vesting terms, 1/48th of the options vest in equal monthly installments starting on March 9, 2026, so the grant becomes fully vested and exercisable on the fourth anniversary of that date, subject to her continued service. This filing reflects an acquisition of derivative securities, not an open-market purchase or sale of common shares.
Aligos Therapeutics, Inc. director and President & CEO Lawrence Blatt received a stock option grant covering 105,840 shares of common stock. The option has an exercise price of $7.03 per share and represents a right to buy, not a market purchase.
According to the vesting terms, 1/48th of the total shares vest in equal monthly installments starting on March 9, 2026, so the option becomes fully vested and exercisable on the fourth anniversary of that date, subject to his continued service. Following this award, he holds 105,840 stock option rights directly in this filing.
Aligos Therapeutics reported a 2025 net loss of $24.2 million, sharply improved from $131.2 million in 2024, mainly due to a non-cash $60.2 million gain from revaluing 2023 common warrants. Operating expenses remained high, with research and development at $69.5 million and general and administrative at $20.7 million.
Cash, cash equivalents and short-term investments totaled $77.8 million as of December 31, 2025, and the company used $82.5 million in operating cash during the year. Management expects existing funds to last only into the third quarter of 2026 and discloses substantial doubt about its ability to continue as a going concern without additional financing.
Aligos raised gross proceeds of $92.1 million in an October 2023 PIPE and approximately $105.0 million in a February 2025 private placement, while advancing its clinical-stage pipeline, including the Phase 2 B-SUPREME trial of HBV candidate pevifoscorvir sodium and Phase 2 work on MASH and coronavirus programs.
Aligos Therapeutics reported recent pipeline progress and sharply improved 2025 financial results. Cash, cash equivalents and investments were $77.8 million as of December 31, 2025, which the company expects will fund planned operations into the third quarter of 2026.
Net loss narrowed to $19.9 million for the fourth quarter of 2025, compared with $82.2 million a year earlier. For the full year 2025, net loss fell to $24.2 million from $131.2 million, helped by $60.2 million of income from the change in fair value of 2023 common warrants.
In its HBV portfolio, the Phase 2 B-SUPREME study of pevifoscorvir sodium completed planned enrollment of 60 HBeAg- participants, with HBeAg+ enrollment ongoing and topline data expected in 2027. ALG-170675 was advanced into IND-enabling studies with partner Amoytop, while preclinical data for ALG-055009 showed additional weight loss when combined with incretin therapies. Aligos also added an Executive Vice President, Chief Commercial Officer to build commercial capabilities.
Aligos Therapeutics, Inc. reported the initial holdings of Principal Accounting Officer Nikhil Aneja on a Form 3. The filing lists several stock option awards giving the right to buy 3,800, 2,640, 7,155 and 3,600 shares, each vesting over four years based on continued service.
Aligos Therapeutics, Inc. received an updated ownership report showing that investment adviser Woodline Partners LP beneficially owns 289,169 shares of Aligos voting common stock, representing 5.4% of the class. This percentage is based on 5,353,582 shares outstanding as of October 31, 2025.
The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser. Woodline states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Aligos.
Sio Capital Management, LLC filed an amended Schedule 13G reporting a passive ownership stake in Aligos Therapeutics, Inc.. Sio beneficially owned 335,937 shares of Aligos common stock as of December 31, 2025, representing 5.46% of the class, based on 6,153,582 shares outstanding as of October 31, 2025. Sio is an investment adviser to affiliated funds that directly hold the shares and has shared voting and dispositive power over them. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Aligos.
Aligos Therapeutics, Inc. announced that its Board of Directors appointed Nikhil Aneja as the company’s Principal Accounting Officer, effective immediately. He replaces Lesley Ann Calhoun in that specific role, while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer.
Mr. Aneja, age 49, has been Aligos’s Vice President, Finance since February 2024. His background includes senior finance and controller positions at CareDx, Blade Therapeutics and Global Blood Therapeutics, and he is a Certified Public Accountant with a Bachelor of Commerce from the University of Delhi.
Aligos Therapeutics (ALGS) filed its quarterly report for the period ended September 30, 2025. The company reported a Q3 net loss of $31.5 million on $0.7 million in revenue from customers, driven by research and development expenses of $23.9 million and general and administrative costs of $5.2 million. A non‑cash change in fair value of 2023 common warrants reduced the warrant liability to $13.4 million as of September 30, 2025.
Liquidity improved after a February 2025 PIPE that generated gross proceeds of $105.0 million (net $101.4 million). Cash, cash equivalents and short‑term investments were $99.1 million as of September 30, 2025. Management states these resources are expected to fund operations into the third quarter of 2026 and indicates substantial doubt about the ability to continue as a going concern absent additional financing.
As of October 31, 2025, shares outstanding were 6,153,582, comprised of 5,353,582 voting and 800,000 non‑voting shares. There were 4,217,432 pre‑funded warrants outstanding as of October 31, 2025 that are immediately exercisable, subject to beneficial ownership limitations.
Aligos Therapeutics (ALGS) reported it furnished a press release via an 8-K under Item 2.02 (Results of Operations and Financial Condition) on November 6, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference in the report.
The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and it will not be incorporated into other filings unless expressly referenced. Aligos’ common stock trades on the Nasdaq Capital Market under the symbol ALGS.